Clinical Report: Bimekizumab in Psoriasis: 3-Year Outcomes

Overview

The BE RADIANT trial demonstrated that bimekizumab significantly improved symptoms and health-related quality of life in patients with moderate to severe plaque psoriasis over a 3-year period. Patients reported improvements as early as week 4, with sustained benefits observed throughout the study duration.

Background

Psoriasis is a chronic inflammatory skin condition that can severely impact patients' quality of life. Effective treatment options are essential for managing symptoms and improving patient outcomes. Bimekizumab, a novel biologic therapy, has shown promise in enhancing symptom control and quality of life in psoriasis patients.

Data Highlights

Key Findings

• Bimekizumab showed higher rates of symptom relief compared to secukinumab at both week 4 and year 1.
• At year 3, 62.2% of patients continuously treated with bimekizumab achieved PASI score of 0 and DLQI score of 0 or 1.
• Patient-reported outcomes indicated significant improvements in itching, skin pain, and scaling.
• Quality of life, as measured by DLQI, improved significantly in patients treated with bimekizumab.
• Switching from secukinumab to bimekizumab at year 1 resulted in continued improvement in symptoms.

Clinical Implications

The findings support the use of bimekizumab as an effective treatment option for patients with moderate to severe plaque psoriasis, demonstrating rapid and sustained improvements in symptoms and quality of life. Clinicians may consider bimekizumab for both initial treatment and as a switch option for patients not achieving desired outcomes with other biologics.

Conclusion

Bimekizumab has proven to be an effective long-term treatment for psoriasis, with significant benefits in symptom control and quality of life maintained over three years. These results underscore its potential role in clinical practice for managing this chronic condition.

References

1. Augustin M, et al., PubMed, 2023 -- Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension
2. Conexiant, 2023 -- Psoriasis Biologics Face Off in Drug Survival Study
3. Clinical Rheumatology, 2022 -- Assessment of ixekizumab's safety and effectiveness in active psoriatic arthritis patients, with and without the use of conventional disease-modifying antirheumatic drugs: Findings from the SPIRIT-P1 and SPIRIT-P2 studies over three years
4. Drugs - Real World Outcomes, 2024 -- Evaluation of Ixekizumab's Effectiveness in Psoriasis Patients Transitioning from IL-23 Inhibitors and Other Biologics: Findings from a Six-Month CorEvitas Study
5. S3 Guideline for the treatment of psoriasis vulgaris, adapted from EuroGuiDerm – part 1: Treatment recommendations and monitoring, PMC, 2023
6. Clinical Rheumatology — Sustained Management of Psoriatic Arthritis with Guselkumab Across Various Domains and Patient Profiles: Insights from a Phase 3 Study Post Hoc Analysis
7. S3 Guideline for the treatment of psoriasis vulgaris, adapted from EuroGuiDerm – part 1: Treatment recommendations and monitoring - PMC
8. Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension - PubMed
9. What are the benefits and risks of systemic treatments for psoriasis ? | Cochrane Skin